TKO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TKO is not a good buy right now at ~206.6. Price is pressing into near-term resistance (R1 ~207.5) with weakening-but-still-negative momentum (MACD below zero), a neutral RSI, and model-based odds skewing to weakness over the next week. With no Intellectia buy signals today and heavy recent insider selling, the risk/reward for an impatient buyer is not attractive at this level.
Trend/Momentum: MACD histogram is -0.709 (below zero) but contracting, which suggests downside momentum is fading, not reversing. RSI(6) ~51.8 is neutral—no clear oversold/overbought edge. Structure/Levels: Post-market ~206.63 is above the pivot (201.15) and approaching resistance R1 (207.51). A clean breakout above ~207.5 would be needed to justify chasing; otherwise, the stock is extended into resistance with room to mean-revert toward pivot/support. Moving averages: Converging MAs point to consolidation rather than a fresh trend leg. Stat/Pattern outlook: Similar-pattern stats imply ~+2.27% next day (only 30% chance), but a more notable -3.84% over the next week, arguing against buying into resistance.
Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
with MACD still negative and no proprietary buy signals.
on 2026-02-25 after hours can increase volatility and reduce near-term predictability.
Latest reported quarter: 2025/Q3. Revenue fell to ~$1.12B (-27.31% YoY), but profitability improved sharply: net income ~$41.0M (+77.23% YoY) and EPS $0.47 (+67.86% YoY). Gross margin rose to ~49.21 (up materially YoY). Overall: top-line contraction in the quarter, but strong margin/earnings expansion—suggesting improved efficiency/mix even as revenue was down.
Recent trend: Predominantly upward revisions to price targets with bullish/positive ratings maintained (JPMorgan Overweight raised to $225; Susquehanna Positive raised to $251; BTIG Buy raised to $250; TD Cowen Buy raised to $245; Wolfe Outperform raised to $227; Morgan Stanley remains more cautious at Equal Weight with $210). Wall Street pros: multi-year compounder narrative, contracted/valuable sports rights, expanding margins/FCF potential, sponsorship and live-events upside. Wall Street cons: after a strong 2025 rally, near-term volatility risk as the market anchors to 2026 guidance; margin expectations have been a sensitivity in prior commentary.
